Natural Killer Cells

[Science Advances] Using an immune “hot” mouse ovarian cancer model, scientists found that cancer-associated-MSCs drove CD8+ T cell tumor immune exclusion and reduced response to anti–PD-L1 immune checkpoint inhibitor via secretion of numerous chemokines.

[Science Signaling] Human and mouse NK cell populations with high responsiveness had low Src homology 2 domain–containing phosphatase-1 (SHP-1) abundance, and a reduction in SHP-1 abundance in NK cells enhanced their responsiveness.

[Shoreline Biosciences] Dendreon Pharmaceuticals and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer and macrophage cellular immunotherapies derived from iPSC for cancer, announced an alliance to advance the future of iPSC-derived cellular therapies.

[Cell Death Discovery] The abundance of myeloid-derived suppressor cells in the tumour microenvironment was associated with therapeutic efficacy and disease outcome. Scientists analyzed the changes in the immune contexture in response to the carbon ion treatment.

[Molecular Therapy-Methods & Clinical Development] Using a non-viral piggyBac transposon technology and human peripheral blood derived primary natural killer (NK) cells, scientists generated CAR-NK cells to target NKG2D ligands.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists described a unique, sophisticated combinatorial platform for glioblastoma (GMB): a cooperative multifunctional immunotherapy based on genetically engineered human NK cells bearing multiple antitumor functions including local tumor responsiveness that addresses key drivers of GBM resistance to therapy.